Literature DB >> 2004

Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs.

N O Fowler, D McCall, T C Chou, J C Holmes, I B Hanenson.   

Abstract

Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either phenothiazines or tricyclic antidepressants. Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman. Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine). Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman. Electrocardiographic T and U wave abnormalities were present in most patients. The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one. The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped. Five of the eight patients were 50 years of age or younger; only one clearly had antecedent heart disease. Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs. A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 2004     DOI: 10.1016/0002-9149(76)90316-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  36 in total

Review 1.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  Effects of licence change on prescribing and poisons enquiries for antipsychotic agents in England and Scotland.

Authors:  D N Bateman; A M Good; R Afshari; C A Kelly
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

3.  Ziprasidone and hypokalemia: a case of 2 predisposing factors for QTc prolongation without development of torsades de pointes.

Authors:  B Rush Simpson; Robert P Albanese
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

Review 4.  Drug effects on the electrocardiogram. A review of their clinical importance.

Authors:  J D Symanski; L S Gettes
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

5.  Thioridazine, diarrhoea and torsades de pointe.

Authors:  M A Denvir; A Sood; R Dow; A J Brady; A C Rankin
Journal:  J R Soc Med       Date:  1998-03       Impact factor: 5.344

6.  Torsade de pointes after pipamperone intoxication.

Authors:  L Bont; H A Bosker; F Brus; J P Yska; F H Bosch
Journal:  Pharm World Sci       Date:  1998-06

7.  Cardiac electrophysiology of four neuroleptics: melperone, haloperidol, thioridazine and chlorpromazine.

Authors:  P Arlock; B Gullberg; S R Olsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-08       Impact factor: 3.000

8.  Treatment of haemodynamic and electrocardiographic side-effects resulting from imipramine toxicity in rats and dogs.

Authors:  V B Fiedler; B Kettenbach; H Göbel; R E Nitz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-08       Impact factor: 3.000

Review 9.  Antipsychotic drugs and QT interval prolongation.

Authors:  Wojciech Zareba; David A Lin
Journal:  Psychiatr Q       Date:  2003

10.  Buflomedil poisoning: five cases with cardiotoxicity.

Authors:  A Legras; R Piquemal; Y Furet; P F Dequin; D Perrotin
Journal:  Intensive Care Med       Date:  1996-01       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.